E. Ruderman, Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis, Current Pharmaceutical Design, vol.11, issue.5, pp.671-684, 2005.
DOI : 10.2174/1381612053381954
URL : http://doi.org/10.2174/1381612053381954

J. Smolen and G. Steiner, Therapeutic strategies in early rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, vol.19, issue.1, pp.473-488, 2003.
DOI : 10.1016/j.berh.2004.08.009

S. Domm, J. Cinatl, and U. Mrowietz, The impact of treatment with tumour necrosis factor-?? antagonists on the course of chronic viral infections: a review of the literature, British Journal of Dermatology, vol.152, issue.Suppl.2, pp.1217-1228, 2008.
DOI : 10.1111/j.1365-2133.2008.08851.x

G. Camussi, E. Albano, C. Tetta, and F. Bussolino, The molecular action of tumor necrosis factor-alpha, European Journal of Biochemistry, vol.140, issue.1, pp.3-14, 1991.
DOI : 10.1016/0006-2952(90)90573-4

V. Kindler, A. Sappino, G. Grau, P. Piguet, and P. Vassalli, The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection, Cell, vol.56, issue.5, pp.731-740, 1989.
DOI : 10.1016/0092-8674(89)90676-4

J. Gomez-reino, L. Carmona, V. Valverde, E. Mola, and M. Montero, Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report, Arthritis & Rheumatism, vol.44, issue.Suppl 9, pp.2122-2127, 2003.
DOI : 10.1002/art.11137

J. Keane, G. S. Wise, R. Mirabile-levens, E. Kasznica, J. Schwieterman et al., Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor ?????Neutralizing Agent, New England Journal of Medicine, vol.345, issue.15, pp.1098-1104, 2001.
DOI : 10.1056/NEJMoa011110

H. Hamdi, X. Mariette, V. Godot, K. Weldingh, A. Hamid et al., Inhibition of antituberculosis T-lymphocyte function with tumour necrosis factor antagonists, Arthritis Research & Therapy, vol.8, issue.4, p.114, 2006.
DOI : 10.1186/ar1994

H. Bruns, C. Meinken, P. Schauenberg, G. Harter, P. Kern et al., Anti-TNF immunotherapy reduces CD8+ T cell???mediated antimicrobial activity against Mycobacterium tuberculosis in humans, Journal of Clinical Investigation, vol.119, issue.5, pp.1167-1177, 2009.
DOI : 10.1172/JCI38482

F. Wolfe and K. Michaud, Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients, Arthritis & Rheumatism, vol.359, issue.6, pp.1740-1751, 2004.
DOI : 10.1002/art.20311

P. Geborek, A. Bladstrom, C. Turesson, A. Gulfe, I. Petersson et al., Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas, Annals of the Rheumatic Diseases, vol.64, issue.5, pp.699-703, 2005.
DOI : 10.1136/ard.2004.030528

E. Baecklund, A. Iliadou, J. Askling, A. Ekbom, C. Backlin et al., Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, Arthritis & Rheumatism, vol.36, issue.3, pp.692-701, 2006.
DOI : 10.1002/art.21675

C. Miceli-richard, N. Gestermann, C. Amiel, J. Sellam, M. Ittah et al., Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies, Arthritis Research & Therapy, vol.11, issue.3, p.77, 2009.
DOI : 10.1186/ar2708

A. Strangfeld, J. Listing, P. Herzer, A. Liebhaber, K. Rockwitz et al., Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti???TNF-?? Agents, JAMA, vol.301, issue.7, pp.737-744, 2009.
DOI : 10.1001/jama.2009.146

J. Sissons, A. Carmichael, N. Mckinney, J. Sinclair, and M. Wills, Human cytomegalovirus and immunopathology, Springer Seminars in Immunopathology, vol.24, issue.2, pp.169-185, 2002.
DOI : 10.1007/s00281-002-0104-0

J. Vaz-santiago, J. Lule, P. Rohrlich, C. Jacquier, N. Gibert et al., Ex Vivo Stimulation and Expansion of both CD4+ and CD8+ T Cells from Peripheral Blood Mononuclear Cells of Human Cytomegalovirus-Seropositive Blood Donors by Using a Soluble Recombinant Chimeric Protein, IE1-pp65, Journal of Virology, vol.75, issue.17, pp.1-657840, 2001.
DOI : 10.1128/JVI.75.17.7840-7847.2001

A. Sylwester, B. Mitchell, J. Edgar, C. Taormina, C. Pelte et al., T cells dominate the memory compartments of exposed subjects, The Journal of Experimental Medicine, vol.70, issue.5, pp.673-685, 2005.
DOI : 10.1182/blood-2003-06-1937

J. Davignon, D. Clement, J. Alriquet, S. Michelson, and C. Davrinche, Analysis of the Proliferative T Cell Response to Human Cytomegalovirus Major Immediate-Early Protein (IEl): Phenotype, Frequeney and Variability*, Scandinavian Journal of Immunology, vol.65, issue.3, pp.247-255, 1995.
DOI : 10.1016/0168-1702(85)90242-4

E. Prieur, D. Betbeder, F. Niedergang, M. Major, A. Alcover et al., Combination of human cytomegalovirus recombinant immediate-early protein (IE1) with 80 nm cationic biovectors: protection from proteolysis and potentiation of presentation to CD4+ T-cell clones in vitro, Vaccine, vol.14, issue.6, pp.511-520, 1996.
DOI : 10.1016/0264-410X(95)00233-Q

R. Vescovini, C. Biasini, F. Fagnoni, A. Telera, L. Zanlari et al., Massive Load of Functional Effector CD4+ and CD8+ T Cells against Cytomegalovirus in Very Old Subjects, The Journal of Immunology, vol.179, issue.6, pp.4283-4291, 2007.
DOI : 10.4049/jimmunol.179.6.4283

L. Gamadia, E. Remmerswaal, J. Weel, F. Bemelman, and R. Van-lier, Primary immune responses to human CMV: a critical role for IFN-gamma -producing CD4+ T cells in protection against CMV disease, Blood, vol.101, issue.7, pp.2686-2692, 2003.
DOI : 10.1182/blood-2002-08-2502

L. Roy, E. Baron, M. Faigle, W. Clement, D. Lewinsohn et al., Infection of APC by Human Cytomegalovirus Controlled Through Recognition of Endogenous Nuclear Immediate Early Protein 1 by Specific CD4+ T Lymphocytes, The Journal of Immunology, vol.169, issue.3, pp.1293-1301, 2002.
DOI : 10.4049/jimmunol.169.3.1293

E. Walter, P. Greenberg, M. Gilbert, R. Finch, K. Watanabe et al., Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor, New England Journal of Medicine, vol.333, issue.16, pp.1038-1044, 1995.
DOI : 10.1056/NEJM199510193331603

H. Einsele, E. Roosnek, N. Rufer, C. Sinzger, S. Riegler et al., Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy, Blood, vol.99, issue.11, pp.3916-3922, 2002.
DOI : 10.1182/blood.V99.11.3916

J. Davignon, P. Castanie, J. Yorke, N. Gautier, D. Clement et al., Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro, J Virol, vol.70, pp.2162-2169, 1996.

E. Amyes, C. Hatton, D. Montamat-sicotte, N. Gudgeon, A. Rickinson et al., T Cell Response to Epstein-Barr Virus during Primary and Persistent Infection, The Journal of Experimental Medicine, vol.70, issue.6, pp.903-911, 2003.
DOI : 10.4049/jimmunol.167.10.5565

D. Schmidt, J. Goronzy, and C. Weyand, CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity., Journal of Clinical Investigation, vol.97, issue.9, pp.2027-2037, 1996.
DOI : 10.1172/JCI118638

E. Bryl, A. Vallejo, C. Weyand, and J. Goronzy, Down-Regulation of CD28 Expression by TNF-??, The Journal of Immunology, vol.167, issue.6, pp.3231-3238, 2001.
DOI : 10.4049/jimmunol.167.6.3231

A. Cope, M. Londei, N. Chu, S. Cohen, M. Elliott et al., Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis., Journal of Clinical Investigation, vol.94, issue.2, pp.749-760, 1994.
DOI : 10.1172/JCI117394

P. Romagnoli, D. Strahan, M. Pelosi, A. Cantagrel, and J. Van-meerwijk, A potential role for protein tyrosine kinase p56lck in rheumatoid arthritis synovial fluid T lymphocyte hyporesponsiveness, International Immunology, vol.13, issue.3, pp.305-312, 2001.
DOI : 10.1093/intimm/13.3.305

M. Prevoo, M. Van-'t-hof, H. Kuper, M. Van-leeuwen, L. Van-de-putte et al., Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.20, issue.1, pp.44-48, 1995.
DOI : 10.1002/art.1780380107

A. Van-gestel, M. Prevoo, M. Van-'t-hof, M. Van-rijswijk, L. Van-de-putte et al., Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria, Arthritis & Rheumatism, vol.38, issue.1, pp.34-40, 1996.
DOI : 10.1002/art.1780390105

E. Choy, C. Smith, C. Dore, and D. Scott, A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal, Rheumatology, vol.44, issue.11, pp.1414-1421, 2005.
DOI : 10.1093/rheumatology/kei031

M. Thewissen, V. Somers, N. Hellings, J. Fraussen, J. Damoiseaux et al., CD4+CD28null T Cells in Autoimmune Disease: Pathogenic Features and Decreased Susceptibility to Immunoregulation, Clinical Immunology, vol.123, pp.6514-6523, 2007.
DOI : 10.1016/j.clim.2007.03.058

E. Bryl, A. Vallejo, E. Matteson, J. Witkowski, C. Weyand et al., Modulation of CD28 expression with anti-tumor necrosis factor ?? therapy in rheumatoid arthritis, Arthritis & Rheumatism, vol.101, issue.10, pp.2996-3003, 2005.
DOI : 10.1002/art.21353

K. Komanduri, S. Donahoe, W. Moretto, D. Schmidt, G. Gillespie et al., Direct Measurement of CD4+ and CD8+ T-Cell Responses to CMV in HIV-1-Infected Subjects, Virology, vol.279, issue.2, pp.459-470, 2001.
DOI : 10.1006/viro.2000.0697

T. Widmann, U. Sester, B. Gartner, J. Schubert, M. Pfreundschuh et al., Levels of CMV Specific CD4 T Cells Are Dynamic and Correlate with CMV Viremia after Allogeneic Stem Cell Transplantation, PLoS ONE, vol.34, issue.11, p.3634, 2008.
DOI : 10.1371/journal.pone.0003634.t001

F. Tubach, D. Salmon, P. Ravaud, Y. Allanore, P. Goupille et al., Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry, Arthritis & Rheumatism, vol.18, issue.7, pp.1884-1894, 2009.
DOI : 10.1002/art.24632
URL : https://hal.archives-ouvertes.fr/inserm-00400633

D. Nathan, P. Angus, and P. Gibson, Hepatitis B and C virus infections and anti-tumor necrosis factor-?? therapy: Guidelines for clinical approach, Journal of Gastroenterology and Hepatology, vol.62, issue.Suppl. 1, pp.1366-1371, 2006.
DOI : 10.1111/j.1440-1746.2006.04559.x

D. Helbling, T. Breitbach, and M. Krause, Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy, European Journal of Gastroenterology & Hepatology, vol.14, issue.12, pp.1393-1395, 2002.
DOI : 10.1097/00042737-200212000-00018

M. Mizuta and M. Schuster, Cytomegalovirus Hepatitis Associated with Use of Anti???Tumor Necrosis Factor????? Antibody, Clinical Infectious Diseases, vol.40, issue.7, pp.1071-1072, 2005.
DOI : 10.1086/428672

J. Allan-yorke, M. Record, C. De-preval, C. Davrinche, and J. Davignon, Distinct pathways for tumor necrosis factor alpha and ceramides in human cytomegalovirus infection, J Virol, vol.72, pp.2316-2322, 1998.